Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis

Liver Transplantation

Volumn 15, Issue 7, 2009, Pages 738-746

  Berenguer, Marina ^a,b,c   Aguilera, Victoria ^a,b   Prieto, Martín ^a,b   Ortiz, Cecilia ^b   Rodríguez, Maria ^a   Gentili, Federica ^a   Risalde, Bias ^b   Rubin, Angel ^a   Cañada, Raquel ^b   Palau, Antonio ^a,b   Rayón, Jose Miguel ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; CYCLOSPORIN A; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTATIC HEPATITIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; CHILD; FEMALE; FIBROSIS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 68349154245     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21707     Document Type: Article

References (22)

1. Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. Curr Opin Org Transplant 2005;10:81-89.
2. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45: 127-143.
3. Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005;9:579-600.
4. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465.
5. Berenguer M, Palau A, Aguilera V, Rayón JM, San Juan F, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transpl 2008;8:679-687.
6. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Signi.cant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
7. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-287.
8. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SNS, Lemonnier C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
9. Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, et al. Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005;20:577-582.
10. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Ef.cacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
11. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Ef.cacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
12. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transplant 2006;6:2348-2355.
13. Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006;82:43-47.
14. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007;13:1100-1108.
15. Abdelmaleck MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:199-207.
16. Bizollon T, Admed SNS, Radenne S, Chevallier M, Chevallier P, Paraz P, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 2003;52:283-287.
17. Sulkowski MS. Management of hepatic complications in HIV-infectedpersons.JInfectDis2008;197(suppl3):S279-S293.
18. Heathcote J. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007;14(suppl 1):82-88.
19. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18.
20. Watashi K, Hijikata M, Hosaka M, Yamagi M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
21. Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, et al. Final results of the ideal (individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J Hepatol 2008; 48(suppl 2):S370.
22. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-379.